This was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal....A statistically significantly shorter survival was observed in patients with a tumor positivity for p4E-BP1 (P < .001) and for IGF1R (P = .023)....The expression of p4E-BP1 was statistically significantly higher in patients with TC than in those with T (57% v 10%; P = .003).